Drug Patents Expiring in 2042
1. Axumin patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11980674 | BLUE EARTH | Imaging of metastatic or recurrent cancer |
Apr, 2042
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 27, 2021 |
Drugs and Companies using FLUCICLOVINE F-18 ingredient
NCE-1 date: 27 May, 2020
Market Authorisation Date: 27 May, 2016
Treatment: Positron emission tomography diagnostic agent in adults with suspected prostate cancer recurrence based on elevated blood prostate specific antigen levels following prior treatment
Dosage: SOLUTION
More Information on Dosage
AXUMIN family patents
2. Ayvakit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12060354 | BLUEPRINT MEDICINES | Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making |
Mar, 2042
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-863) | Jun 16, 2024 |
| New Indication(I-864) | Jun 16, 2024 |
| New Chemical Entity Exclusivity(NCE) | Jan 09, 2025 |
| New Indication(I-912) | May 22, 2026 |
| Orphan Drug Exclusivity(ODE-366) | Jan 09, 2027 |
| Orphan Drug Exclusivity(ODE-356) | Jun 16, 2028 |
| Orphan Drug Exclusivity(ODE-434) | May 22, 2030 |
Drugs and Companies using AVAPRITINIB ingredient
NCE-1 date: 10 January, 2024
Market Authorisation Date: 16 June, 2021
Treatment: Treatment of unresectable or metastatic gastrointestinal stromal tumor (gist) harboring a platelet-derived growth factor receptor alpha (pdgfra) exon 18 mutation
Dosage: TABLET
More Information on Dosage
AYVAKIT family patents
3. Bortezomib patent
expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11752164 | MAIA PHARMS INC | Bortezomib compositions |
Sep, 2042
(17 years from now) | |
| US11679119 | MAIA PHARMS INC | Bortezomib compositions |
Sep, 2042
(17 years from now) | |
| US12005069 | MAIA PHARMS INC | Bortezomib compositions |
Sep, 2042
(17 years from now) | |
Drugs and Companies using BORTEZOMIB ingredient
Market Authorisation Date: 27 July, 2022
Treatment: Treatment of adult patients with multiple myeloma
Dosage: SOLUTION
More Information on Dosage
BORTEZOMIB family patents
4. Daybue patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11827600 | ACADIA PHARMS INC | Crystalline forms of trofinetide |
Jul, 2042
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 10, 2028 |
| Orphan Drug Exclusivity(ODE-425) | Mar 10, 2030 |
Drugs and Companies using TROFINETIDE ingredient
NCE-1 date: 11 March, 2027
Market Authorisation Date: 10 March, 2023
Treatment: Treatment of rett syndrome or a symptom thereof
Dosage: SOLUTION
More Information on Dosage
DAYBUE family patents
5. Defencath patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11738120 | CORMEDIX | Synthesis of taurolidine, purity profiles and polymorphs |
Apr, 2042
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 15, 2028 |
| Generating Antibiotic Incentives Now(GAIN) | Nov 15, 2033 |
Drugs and Companies using HEPARIN SODIUM; TAUROLIDINE ingredient
NCE-1 date: 15 November, 2032
Market Authorisation Date: 15 November, 2023
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
DEFENCATH family patents
6. Exparel patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11931459 | PACIRA PHARMS INC | Treatment of pain in pediatric patients by administration of sustained-release liposomal anesthetic compositions |
Mar, 2042
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 28, 2014 |
| New Indication(I-771) | Apr 06, 2021 |
| New Patient Population(NPP) | Mar 22, 2024 |
| New Indication(I-929) | Nov 09, 2026 |
Drugs and Companies using BUPIVACAINE ingredient
Market Authorisation Date: 28 October, 2011
Treatment: A method of treating pain by administering bupivacaine via local infiltration in pediatric patients aged 6 to less than 12 years old undergoing cardiac surgery
Dosage: INJECTABLE, LIPOSOMAL
How can I launch a generic of EXPAREL before it's drug patent expiration?
More Information on Dosage
EXPAREL family patents
7. Galafold patent expiration
Can you believe GALAFOLD received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11833164 | AMICUS THERAP US | Methods of treating Fabry disease in patients having a mutation in the GLA gene |
Jan, 2042
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 10, 2023 |
| Orphan Drug Exclusivity(ODE-205) | Aug 10, 2025 |
Drugs and Companies using MIGALASTAT HYDROCHLORIDE ingredient
NCE-1 date: 10 August, 2022
Market Authorisation Date: 10 August, 2018
Treatment: The treatment of fabry patients
Dosage: CAPSULE
How can I launch a generic of GALAFOLD before it's drug patent expiration?
More Information on Dosage
GALAFOLD family patents
8. Lumryz patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11583510 | AVADEL CNS | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
Feb, 2042
(17 years from now) | |
| US11779557 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Mar, 2042
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 01, 2026 |
| Orphan Drug Exclusivity(ODE-431) | May 01, 2030 |
| Orphan Drug Exclusivity(ODE-494) | Oct 16, 2031 |
Drugs and Companies using SODIUM OXYBATE ingredient
Market Authorisation Date: 01 May, 2023
Treatment: Treatment of narcolepsy, cataplexy or excessive daytime sleepiness using a once-nightly gamma-hydroxybutyrate formulation; Treatment of cataplexy or excessive daytime sleepiness in patients with narco...
Dosage: FOR SUSPENSION, EXTENDED RELEASE
More Information on Dosage
LUMRYZ family patents
9. Ogsiveo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11612588 | SPRINGWORKS | Chlorinated tetralin compounds and pharmaceutical compositions |
Jul, 2042
(17 years from now) | |
| US12110277 | SPRINGWORKS | Synthesis of nirogacestat |
Jul, 2042
(17 years from now) | |
| US11504354 | SPRINGWORKS | Chlorinated tetralin compounds and pharmaceutical compositions |
Jul, 2042
(17 years from now) | |
| US11807611 | SPRINGWORKS | Chlorinated tetralin compounds and pharmaceutical compositions |
Sep, 2042
(17 years from now) | |
| US11844780 | SPRINGWORKS | Chlorinated tetralin compounds and pharmaceutical compositions |
Sep, 2042
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 27, 2028 |
| ODE*(ODE*) | Nov 27, 2030 |
| Orphan Drug Exclusivity(ODE-452) | Nov 27, 2030 |
Drugs and Companies using NIROGACESTAT HYDROBROMIDE ingredient
NCE-1 date: 28 November, 2027
Market Authorisation Date: 27 November, 2023
Treatment: Treatment of adult patients with progressing desmoid tumors
Dosage: TABLET
More Information on Dosage
OGSIVEO family patents
10. Ponvory patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11951097 | VANDA PHARMS INC | Methods of treating multiple sclerosis |
Oct, 2042
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 18, 2026 |
Drugs and Companies using PONESIMOD ingredient
NCE-1 date: 18 March, 2025
Market Authorisation Date: 18 March, 2021
Treatment: Treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults being treated with a ...
Dosage: TABLET
More Information on Dosage
PONVORY family patents
11. Qinlock patent expiration
Can you believe QINLOCK received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11779572 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Oct, 2042
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 15, 2025 |
| Orphan Drug Exclusivity(ODE-298) | May 15, 2027 |
Drugs and Companies using RIPRETINIB ingredient
NCE-1 date: 15 May, 2024
Market Authorisation Date: 15 May, 2020
Treatment: Treatment of gastrointestinal stromal tumors in patients having pre-existing severe hepatic impairment and suffering from an adverse event while being administered ripretinib daily
Dosage: TABLET
More Information on Dosage
QINLOCK family patents
12. Rezurock patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12097202 | KADMON PHARMS LLC | Methods of administering Belumosudil for treatment of chronic graft versus host disease |
Jul, 2042
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 16, 2026 |
| Orphan Drug Exclusivity(ODE-362) | Jul 16, 2028 |
Drugs and Companies using BELUMOSUDIL MESYLATE ingredient
NCE-1 date: 16 July, 2025
Market Authorisation Date: 16 July, 2021
Treatment: Treatment of chronic graft-versus-host disease (chronic gvhd) after failure of at least two prior lines of systemic therapy in adult and pediatric patients 12 years and older with a grade 3 infection ...
Dosage: TABLET
More Information on Dosage
REZUROCK family patents
13. Sezaby patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11857683 | SUN PHARM INDS INC | Stabilization of phenobarbital sodium for injection |
Apr, 2042
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-414) | Nov 17, 2029 |
Drugs and Companies using PHENOBARBITAL SODIUM ingredient
Market Authorisation Date: 17 November, 2022
Treatment: Method of treating neonatal seizures
Dosage: POWDER
More Information on Dosage
SEZABY family patents
14. Sunosi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11793776 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(18 years from now) | |
| US11771666 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(18 years from now) | |
| US11771667 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(18 years from now) | |
| US12064411 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(18 years from now) | |
| US12102609 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(18 years from now) | |
| US12090126 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(18 years from now) | |
| US11872203 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(18 years from now) | |
| US12005036 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(18 years from now) | |
| US11872204 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(18 years from now) | |
| US12036194 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(18 years from now) | |
| US11779554 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(18 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 17, 2024 |
| Orphan Drug Exclusivity(ODE-254) | Jun 17, 2026 |
Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient
NCE-1 date: 18 June, 2023
Market Authorisation Date: 17 June, 2019
Treatment: Treatment of excessive daytime sleepiness in a breast-feeding patient while reducing infant exposure to solriamfetol
Dosage: TABLET
How can I launch a generic of SUNOSI before it's drug patent expiration?
More Information on Dosage
SUNOSI family patents
15. Talicia patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11878011 | REDHILL | Method for eradicating Helicobacter pylori infection in patients regardless of body mass index |
May, 2042
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 01, 2022 |
| Generating Antibiotic Incentives Now(GAIN) | Nov 01, 2027 |
Drugs and Companies using AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN ingredient
Market Authorisation Date: 01 November, 2019
Treatment: Treatment of helicobacter pylori infection using the administered dosage forms in adults with different body mass index determinations
Dosage: CAPSULE, DELAYED RELEASE
More Information on Dosage
TALICIA family patents
16. Tezruly patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11224572 | NOVITIUM PHARMA | Stable oral liquid composition of terazosin |
Jan, 2042
(17 years from now) | |
Drugs and Companies using TERAZOSIN HYDROCHLORIDE ingredient
Market Authorisation Date: 29 July, 2024
Treatment: Treatment of symptomatic benign prostatic hyperplasia (bph) in patients who are in need of a liquid composition of terazosin
Dosage: SOLUTION
More Information on Dosage
TEZRULY family patents
17. Tyvaso patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11826327 | UNITED THERAP | Treatment for interstitial lung disease |
Feb, 2042
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Jul 30, 2012 |
| Orphan Drug Exclusivity(ODE) | Jul 30, 2016 |
| M(M-145) | May 20, 2017 |
| New Indication(I-856) | Mar 31, 2024 |
Drugs and Companies using TREPROSTINIL ingredient
Market Authorisation Date: 30 July, 2009
Treatment: Method of treating pulmonary hypertension associated with interstitial lung disease by administering treprostinil or a salt thereof by inhalation using a device
Dosage: SOLUTION
More Information on Dosage
TYVASO family patents
18. Tyvaso Dpi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11826327 | UNITED THERAP | Treatment for interstitial lung disease |
Feb, 2042
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 23, 2025 |
Drugs and Companies using TREPROSTINIL ingredient
Market Authorisation Date: 23 May, 2022
Treatment: Method of treating pulmonary hypertension associated with interstitial lung disease by administering treprostinil or a salt thereof by inhalation using a device
Dosage: POWDER
More Information on Dosage
TYVASO DPI family patents
19. Vevye patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12059449 | HARROW EYE | Ophthalmic composition for treatment of dry eye disease |
Apr, 2042
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 30, 2026 |
Drugs and Companies using CYCLOSPORINE ingredient
Market Authorisation Date: 30 May, 2023
Treatment: Increase tear production in patients with keratoconjunctivitis sicca (dry eye).
Dosage: SOLUTION
More Information on Dosage
VEVYE family patents
20. Vivimusta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11844784 | AZURITY | Stable pharmaceutical compositions of bendamustine |
Jul, 2042
(17 years from now) | |
Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 07 December, 2022
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
VIVIMUSTA family patents
21. Xelstrym patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11559501 | NOVEN PHARMS INC | Transdermal amphetamine compositions with low levels of carbamate |
Jan, 2042
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 22, 2025 |
Drugs and Companies using DEXTROAMPHETAMINE ingredient
Market Authorisation Date: 22 March, 2022
Treatment: NA
Dosage: SYSTEM
More Information on Dosage
XELSTRYM family patents
22. Zunveyl patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11795176 | ALPHA COGNITION | Solid forms of Alpha-1062 gluconate |
Jan, 2042
(17 years from now) | |
Drugs and Companies using BENZGALANTAMINE GLUCONATE ingredient
Market Authorisation Date: 26 July, 2024
Treatment: Treatment of mild to moderate dementia of the alzheimer's type
Dosage: TABLET, DELAYED RELEASE
More Information on Dosage
ZUNVEYL family patents